Reviva Pharmaceuticals Holdings Inc
RVPH
查看详细走势图
0.286USD
+0.032+12.35%
收盘 02/06, 16:00（美东）报价延迟15分钟
27.60M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+12.35%
5天
-2.02%
1月
-17.24%
6月
-33.17%
今年开始到现在
+2.69%
1年
-86.23%
查看详细走势图
TradingKey Reviva Pharmaceuticals Holdings Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Reviva Pharmaceuticals Holdings Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名181/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价5.56。中期看，股价处于下降通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Reviva Pharmaceuticals Holdings Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Reviva Pharmaceuticals Holdings Inc亮点
亮点风险
Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).
估值高估
公司最新PE估值-0.65，处于3年历史高位
机构减仓
最新机构持股12.79M股，环比减少27.11%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值3.20M
活跃度降低
近期活跃度降低，过去20天平均换手率0.43
分析师目标
根据
7
位分析师
买入
评级
5.563
目标均价
+1900.18%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Reviva Pharmaceuticals Holdings Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Reviva Pharmaceuticals Holdings Inc简介
Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).
公司代码RVPH
公司Reviva Pharmaceuticals Holdings Inc
CEOBhat (Laxminarayan)
网址https://revivapharma.com/
相关品种
